Second edition · September 2026 · regulatory cut-off 7 September 2026
ICH is not law. This guide tells you, sentence by sentence, where the text has force — and through which legal act.
In the European Union, ICH Q9(R1) and Q10 sit in Part III of EudraLex Volume 4, which the Volume 4 Introduction describes verbatim as "not detailed guidelines", and the GMP Guide Chapter 1 calls that subject matter "while optional". This guide never writes "ICH Q10 requires X" without naming the act and the jurisdiction that actually impose the duty. 27 chapters in six parts, 250 pages in the English edition and 247 in the Italian, 17 editable tools and 134 tables, at €129.
250 pages (ENG) · 247 (ITA) · A4 PDF27 chapters in six parts + 5 appendices17 editable tools per language897 regulatory labels per edition134 tablesSix jurisdictions: EU · UK · US · CA · CH · JPRegulatory cut-off 7 September 2026
Two separate editions, not two languages in one file. The guide and the toolkit exist in two editions only, Italian and English, with identical structure, numbering, tables and references: at checkout you choose the variant ITA - Italiano or ENG - English, at the same price. Your purchase gives you the edition you choose.
The guide
27 chapters in six parts that read the Q series for what it is: the Q8(R2)-Q9(R1)-Q10 trilogy clause by clause, Q12 and lifecycle management, the part of the series that genuinely matters — Q2(R2) and Q14, Q7 and Part II, Q11 and Q13, the Q3 family, Q5A(R2) and Q6 — the new Q1 [draft], and finally how all of it is demonstrated in an inspection. Every chapter states what the text says → with which verb → in which jurisdiction that sentence has force → through which act → what the company has to decide → where the decision is recorded, and closes with the table of decisions it produces.
The toolkit
17 editable tools per language: 10 Excel workbooks with live formulas, data validation and instruction sheets, and 7 Word documents with model text, revision history and an approval line. Every checklist row carries a precise regulatory reference — a row without one does not go in — and every field that depends on product, process, site or jurisdiction is <to be defined>, with instructions alongside on what to base the decision on.
Lifetime updates
The picture moves, and the next checkpoints already have an address: Step 4 of the new Q1 [draft] is expected at the ICH meeting in Prague on 14-18 November 2026, and the transitional exclusion of variation codes Q.I.e.7 and Q.II.g.7 is declared temporary by the very Q&A that imposes it. When the texts change you receive the revised guide and toolkit at no extra cost.
€129, and the distance from the first edition is measurable
The first edition was 95 pages with no toolkit at €89. This is the second edition, September 2026: 250 pages in the English edition, 247 in the Italian, 27 chapters in six parts, 5 appendices, 134 tables and 17 editable tools per language. The first edition declared no regulatory cut-off, titled five checklists "Implementing Q8 / Q9 / Q10 / Q12", and promised "common errors flagged by inspectors" that the text did not contain. This edition fixes all three defects, and says so inside the book.
The price is €129.00, with a regulatory verification cut-off of 7 September 2026 and primary sources accessed on 8 September 2026. One edition is sold per variant — ITA - Italiano or ENG - English — at the same price. Buyers of the first edition receive this one at no extra cost.
The 17 tools, one by one
Ten Excel workbooks and seven Word documents per edition. No operational value is pre-loaded, in any of the seventeen tools. Thresholds, scores, risk scales, severity matrices, frequencies, limits, acceptance criteria, batch numbers and durations are all <to be defined>, and the reason is textual: Q9(R1) §5.3 warns that subjectivity also enters "when tools have poorly designed risk scoring scales", and §5.1 requires scores to be "based on an appropriate use of evidence, science and knowledge". A pre-loaded number becomes the house default without anyone having decided it. Next to every placeholder the sheet explains on what basis the value is to be decided and what makes it defensible. No tool reproduces or adapts any table, figure, matrix or scale from ISO, PDA, ISPE or ICH, and the verb "implement" appears in no tool, sheet or section title.
EXCEL01 · Q9(R1) gap assessment — clause by clause (ch. 7)
Compares what Q9(R1) says with what the quality risk management system already does. Sheets for clauses 1-8, Annex I and Annex II. Completed by QA, approved by the Head of Quality. Every row carries the Q9(R1) clause and the act of the jurisdiction that makes it relevant: without that second field a gap is not a gap, it is a preference.
EXCEL02 · Quality risk register (ch. 8)
The risk assessment register with controls and review status, referenced to Q9(R1) §4.3-4.6, §5.1 and §5.3 plus the GMP provision of the jurisdiction. Every scale, score, threshold and frequency remains to be built: the sheet carries the instructions for building them, not the values.
EXCEL03 · QTPP and CQA register (ch. 5)
QTPP, CQAs and the traceability from one to the other, for pharmaceutical development and formulation. References to Q8(R2), Part II (Annex), §2.1, §2.2 and the §4 glossary. Every limit, range or distribution cell is a placeholder: an attribute is critical when its criticality is justified, not when the cell is full.
EXCEL04 · Design space and control strategy register (ch. 6)
Control strategy elements with their justification and regulatory status, separating what is stated in the dossier from what lives in the quality system — the distinction that decides whether a change costs a variation. Sheets: control strategy, PAR, design space if claimed, RTRT if used. References Q8(R2), Part II, §2.4, §2.4.5, §2.5.
EXCEL05 · Q10 gap assessment on the PQS (ch. 9)
Separates what regional GMP already requires from what goes beyond it and which, by Q10 §1.1's own words, is "optional". Sheets on the four elements, the two enablers and the four lifecycle stages, with a "regional GMP / optional excess" column. It is the tool that stops a company from recording as a non-conformity a choice the text calls voluntary.
EXCEL06 · Established Conditions register (ch. 12)
Elements with an internal qualification, a dossier reference and a variation category set by the jurisdiction's framework, not by the applicant. Sheets: process, analytical procedures, dossier references. References Q12 §3.2.1, §3.2.2, §3.2.3 plus the national variations framework.
WORD07 · PLCM document builder (ch. 13)
The tabular form of Q12 §5.4, filed in CTD Module 3.2.R and submitted through a Type II variation. Sections: ECs, reporting categories, PACMPs, commitments. It must contain the statement that future variation types will follow the classification in the Annex to the Variations Guidelines. References: Q12 §5.1 and §5.4; Article 6a of the revised Variations Regulation; chapters Q.I.e and Q.II.g of Guidelines C/2025/5045; Q&A EMA/CHMP/QWP/7093/2026.
WORD08 · PACMP template (ch. 14)
Structures the protocol to Q12 §4.3: the planned change, the verification studies, the criteria, the proposed reporting category. References Q12 §4.1-4.5; for the EU, Q&A EMA/CHMP/QWP/586330/2010 Rev 1, effective 15 January 2026; for the US, 21 CFR 314.70(e). Acceptance criteria remain to be built, with instructions for building them.
EXCEL09 · Multi-jurisdiction applicability matrix (ch. 4)
The tool nineteen chapters point back to: which Q series documents apply to this site and these products, and with what force. Sheets: scope, legal force, calendar, Q12. Every row carries the national act that makes the document relevant, with its date.
EXCEL10 · Q1 readiness assessment (ch. 24)
A plan measured in weeks relative to two triggers: E1, verifying Step 4 in the press release of the ICH meeting; E2, verifying regional adoption in your own jurisdiction. Sheets: phases 0-3, source monitoring, decisions. The header states that the reference document is [draft] and that readiness is not compliance. Every absolute date and every duration remains to be defined.
EXCEL11 · Stability study inventory (ch. 22)
Maps what exists today against what the draft would expect: ongoing studies, comparison, gap and action. No storage condition, no minimum data period and no significant-change threshold goes into the sheet, because they would come from a draft text. References Q1A(R2)-Q1E and Q5C for current practice.
EXCEL12 · Analytical procedure lifecycle register (ch. 16)
Identification, ATP, validation and changes, for QC and analytical development. References Q14 §3, §6, §7 and Q2(R2) for validation. On Established Conditions it flags the European and the Canadian reservations, because the same technical choice does not produce the same variation category in the two jurisdictions.
WORD13 · Change management SOP (ch. 14)
The procedure that carries every Q12 tool: initiation, assessment, classification, approval, implementation, effectiveness check. References Q10 §3.2.3 and the national variations framework. No threshold, no risk class and no cycle time arrives pre-loaded.
WORD14 · Quality risk management SOP (ch. 7)
Initiation, hazard identification, analysis, evaluation, control, communication, review — plus the two sections the R1 revision makes necessary: the formality of the process and the management of subjectivity. References Q9(R1) §4, §5.1, §5.2, §5.3, §6.1 and the GMP provision of the jurisdiction.
WORD15 · Management review and product quality review pack (ch. 9)
Agenda, inputs, expected decisions and minutes, for senior management and QA. References Q10 §3.2.4 and §1.7 plus the GMP provision that requires the review. No pre-loaded frequency: periodicity is justified, not inherited from a template.
WORD16 · Q series training and competence pack (ch. 27)
Modules, learning objectives, comprehension checks and a competence record, built on the documents that tool 09 has declared applicable. It is the evidence that the team knows the applicable text and can say why it is applicable. References Q10 §1.7 and Q9(R1) §4.1.
WORD17 · Inspection simulation kit (ch. 27)
Running order, roles, question bank, observation grid and debriefing minutes. Every question points back to the clause that justifies it, and none goes in without that pointer: you rehearse against questions built from citable text, not invented ones. No scoring, no pass threshold, no duration.
You use it tomorrow morning
| The situation | What you use |
|---|
| Our procedures state that ICH Q10 is mandatory in Europe | Chapters 9 and 10 + Tool 05: in the EU, Q10 is reproduced in Part III of EudraLex Volume 4, which the Volume 4 Introduction calls "not detailed guidelines", and Chapter 1 §1.2 describes it as material "which while optional". The gap assessment separates what regional GMP already requires from what goes beyond it |
| We want to submit a PLCM document in the European Union | Chapters 11-13 + Tool 07: since 15 January 2026 the PLCM document can be used in the EU — optional, through a Type II variation, filed in Module 3.2.R — on the chain of Article 6a, Guidelines C/2025/5045 chapters Q.I.e and Q.II.g, and Q&A EMA/CHMP/QWP/7093/2026. The chapter also names the two variation codes the Q&A forbids using |
| We have to decide what our Established Conditions are | Chapter 12 + Tools 06 and 12: the Q12 §3.2.1 definition and who actually applies it in each of the six jurisdictions — in the EU the 2026 Q&A states that the term "is not specifically defined in the legal framework of the EU" and refers classification back to the Annex to the Variations Guidelines |
| We run stability and we do not know whether to touch the protocols | Chapters 21-24 + Tools 10 and 11: the new Q1 is [draft] and at the cut-off creates no obligation anywhere. The plan is measured in weeks relative to two triggers, and the default outcome of every readiness activity is "do not change" — a decision to be reasoned and recorded, not one to be left to happen |
| A client is asking us about readiness for the new Q1 | Chapters 21 and 23 + Tool 10: what the draft would absorb (Q1A-F and Q5C), where to verify the Step 4 expected in Prague on 14-18 November 2026, and the discrepancy between the ICH text and the Federal Register notice over which guidances are listed as superseded |
| Our SOPs still cite Annex 20 as the source of an obligation | Chapters 7 and 10: Annex 20 no longer appears in the official EudraLex Volume 4 index, which jumps from Annex 19 to Annex 21, and the corresponding content has been in Part III since 26 July 2023. The chapter also supplies the defensible wording, because no formal act of repeal has been found |
Our source register cites EMA/CHMP/ICH/82072/2006 and nothing else | Chapters 4 and 16: that code covers both Q2(R1) and Q2(R2) and on its own does not identify the version. The same applies to 24235/2006 (Q9 and Q9(R1)), 82260/2006 (Q3C(R8) and Q3C(R9)) and 167068/2004 (Q8 and Q8(R2)) |
| We have sites and filings across several jurisdictions | Chapter 4 and Part IV + Tool 09: six jurisdictions — European Union, United Kingdom, United States, Canada, Switzerland, Japan — with the status document by document and the national act that carries it. It is the matrix you use to decide what applies to which site and which product |
| We have an inspection in two weeks | Chapters 25 and 27 + Tools 16 and 17: what the sources declare assessable in an inspection, clause by clause, and the question bank with the expected evidence. Including the two Q10 sentences, §1.4 and §1.7(c), that speak of effectiveness, not of conformity to a list of clauses |
| We need to redo the gap assessment on the Q series | Chapter 26 + Tools 01 and 05: the method that avoids the standard failure of treating every ICH clause as a requirement, and so of producing a written list of supposed non-conformities that works against its own author in an inspection |
Why a guide on the Q series is worth exactly as much as its precision about three dates
Three dates, and they are never merged into one. ICH Step 4 is the adoption of the harmonised text, and it produces no legal effect. Regional adoption is publication in the jurisdiction — for the EU, the First published field on the EMA page. Applicability is the Legal effective date field, the only date that says when a text starts to apply. In this guide a dash in one of those columns means "does not exist, or not found in a primary source", never "same as the previous column". Most of what is written wrongly about the Q series comes from collapsing those three dates into one.
ICH is not law, and the book never states an obligation without naming the act that imposes it. In the European Union, Q9(R1) and Q10 are reproduced in Part III of EudraLex Volume 4, which the Volume 4 Introduction calls "not detailed guidelines" and "source of information on current best practices"; GMP Guide Chapter 1 §1.2 describes extending the quality system to pharmaceutical development as material "which while optional". The European obligation runs through Chapter 1 of Part I and Directive (EU) 2017/1572, not through an ICH document — which is why a European inspector does not cite a breach of ICH Q9(R1), but a breach of Chapter 1, of Annex 15 or of Annex 1.
On 15 January 2026 the status of one Q12 tool changed, not the status of the guideline. From that date the PLCM document can be used in the European Union: optional, submitted through a Type II variation, filed in CTD Module 3.2.R, enabled by Article 6a of the revised Variations Regulation and by chapters Q.I.e and Q.II.g of Guidelines C/2025/5045, and explained by Q&A EMA/CHMP/QWP/7093/2026. What was not taken up are the risk-based approaches of Chapter 3.2.3 for defining Established Conditions. And the joint DG SANTE-EMA note EMA/CHMP/ICH/78332/2020, which in 2020 declared both incompatible, is still published and has never been withdrawn: chapter 13 reproduces both documents in full and does not choose for the reader.
The new Q1 is a draft, and this guide sells readiness, not compliance. The text is the Step 2b draft of 11 April 2025, consultation closed on 30 July 2025; Step 4 is expected at the ICH meeting in Prague on 14-18 November 2026, and the Rio de Janeiro minutes use the verb aims, not will. As at 3 June 2026, 91 % of consultation comments were resolved, and the topics still open are not editorial ones: "extrapolation for biologics, end-to-end stability, and statistical matters". Every mention of the new Q1 in the book and in the toolkit carries the [draft] label, and complying today means complying with Q1A(R2)-Q1E and with Q5C, which remains in force until regional Step 5.
Annex 20 no longer appears in the EudraLex Volume 4 index — and it never imposed a requirement anyway. The list of annexes jumps from Annex 19 to Annex 21 and the two historic PDF URLs return 404; the corresponding content, ICH Q9 in its R1 version, is published in Part III with effect from 26 July 2023. No Commission act formally suppressing Annex 20 has been found, and the book does not assert a repeal the public record will not support. Anyone writing "the risk-based approach required by Annex 20" — the wording that appeared on this guide's own first-edition product page — is wrong twice over: the annex is no longer in the index, and Part III, by its own words, does not "require".
There is no published statistic of inspection findings by Q series clause, and the book says so rather than filling the gap. A finding is written against the act that imposes the obligation in the jurisdiction of the inspection, not against the international text that interprets it: there is therefore no counting unit called "ICH clause". Instead of plausible invented findings, chapter 25 sets out what the sources declare assessable in an inspection, clause by clause, alongside what those same clauses do not say. The rest of the apparatus is of the same kind: 17 labels — nine on the status of the document, eight on the nature of the assertion — used 897 times per edition, a source register carrying code, version, step, the three dates, status, URL and access date, a status matrix by jurisdiction, and 132 tracked decisions with who decides, where it is recorded and with which tool.
Inside the guide
Part I — What ICH is, and what it is not (ch. 1-4). How to use the guide, the reading paths and the label system; the calendar of what changed from 2023 and what changes by 2028, with the three dates kept apart; how an ICH guideline becomes — or fails to become — mandatory, from Step 1 to Step 5 and regional adoption; and the inventory of the whole Q series, document by document, with status and force.
Part II — The trilogy, read clause by clause (ch. 5-10). Q8(R2): pharmaceutical development, QTPP, CQAs — and the verb Q8 uses about itself, including the "is not necesserily expected" [sic] of Appendix 1. Design space and control strategy, and what claiming them actually commits you to. Q9(R1): what the revision changed, and its four areas — subjectivity, formality, decision making, product availability. Q10: the four elements and the two enablers, what Q10 declares it does not replace, and where it lives in the European Union.
Part III — Q12 and the lifecycle (ch. 11-15). The Q12 tools and what they promise; Established Conditions and who really defines them in each jurisdiction; the PLCM document and the chain of acts of 15 January 2026, with the two mutually exclusive EMA documents both published at the cut-off; PACMPs and post-approval change management, whose European history does not start with Q12; and Q12 outside the European Union — United States, Canada, Japan, Switzerland, United Kingdom.
Part IV — The rest of the series that genuinely matters (ch. 16-20). Q2(R2) and Q14, the analytical pair, and the EMA code that does not identify the version; Q7 and Part II, GMP for active substances, including the file-naming error on the EudraLex page; Q11 and Q13; the Q3 family — impurities, residual solvents, elemental — with the two guidelines that can change their own numbers without reopening the ICH process, and Q3E in [draft]; Q5A(R2), Q6 and specifications.
Part V — The new Q1: readiness for November 2026 (ch. 21-24). What the new Q1 [draft] is and which guidelines it would absorb, with the four independent proofs of its real status at the cut-off; what changes against Q1A(R2); Q5C inside Q1, the biologics question and the discrepancy between the ICH text and the Federal Register notice; and the readiness plan in weeks relative to two triggers, so the countdown starts the day the plan is adopted.
Part VI — Proving it (ch. 25-27). What an inspector actually looks at, with published figures and their denominators and a declared absence where the data does not exist; the method for a Q series gap assessment, and why a title that presumes the obligation condemns the document before its content does; and inspection readiness with the questions and the expected evidence, starting from "why don't you have a design space?".
Plus 5 appendices. The source register, with exact title, ICH code, EU code, version or step, the three dates, status, URL and access date, plus the [does not exist] entries and the detail behind every [status differs] entry; the regulatory status matrix by jurisdiction, with the act that carries each document; the 132 decisions the guide produces, indexed chapter by chapter; the data sheets for the 17 tools; and the glossary, including the terms with no citable ICH definition and the codes that do not identify a version.
Read 19 pages before you buy
The free extract is made of real pages, not a sales summary: the two label families with their legend, the full table of contents with real page numbers, the opening of the chapter on the PLCM document and 15 January 2026, the page that states the [draft] status of the new Q1, and the complete list of the 17 tools with their source chapter and intended user. 19 pages in the English edition, 20 in the Italian.
Specifications
| Format | A4 PDF — 250 pages (ENG edition) · 247 pages (ITA edition) |
| Edition | Second edition · September 2026 · version 2.0. Supersedes the first edition (95 pages, no toolkit). |
| Structure | 27 chapters in six parts + 5 appendices · 134 tables |
| Documents covered | The whole Q series: Q1A(R2)-Q1F and the new Q1 [draft], Q2(R2), the Q3 family with Q3E [draft], Q4B and its annexes, Q5A(R2)-Q5E, Q6A and Q6B, Q7 and its Q&As, Q8(R2), Q9(R1), Q10, Q11, Q12, Q13, Q14 |
| Jurisdictions covered | European Union, United Kingdom, United States, Canada, Switzerland, Japan — with the status document by document and the national act that carries it |
| Toolkit | 17 editable tools per language: 10 Excel workbooks and 7 Word documents. No pre-loaded operational values, no thresholds, no scoring scales |
| Editions | The guide and the toolkit exist in two separate editions, Italian and English, identical in structure: you choose the variant ITA - Italiano or ENG - English, at the same price |
| Label system | 17 labels — 9 on the status of the document, 8 on the nature of the assertion — used 897 times per edition |
| Sources | Full register in Appendix A: exact title, ICH code, EU code, version or step, the three dates, status, URL and access date |
| Decisions | 132 tracked decisions: who decides, the input, where it is recorded, with which toolkit tool |
| Regulatory cut-off | 7 September 2026 · primary sources accessed 8 September 2026 |
| Free preview | 19 pages (ENG) · 20 pages (ITA) |
| Price | €129.00 |
| Delivery and licence | Immediate download after purchase. Individual use, internal to the purchasing company. Digital product: nothing is shipped. |
Who it is for. QA Managers and Heads of Quality, Regulatory Affairs CMC, Qualified Persons, pharmaceutical development and formulation, analytical development and quality control, validation, auditors, consultants and CDMOs. It is written for people who already have the guidelines and have to apply them: it does not summarise or paraphrase them, because the texts of Q8(R2), Q9(R1), Q10 and Q12 are free to download from the official sites. It answers two different questions: where that text has force and through which act, and what it means for the person who has to decide.
Who it is not for. It is not the text of the ICH guidelines, which should be read and kept to hand. It is not a how-to manual on any single subject: it states what the Q series says about that subject and where the sentence has force, not how to validate a process or develop a method — dedicated guides exist in the catalogue, and the boundary is declared every time the text reaches it. It contains no operational values, thresholds or scoring scales, neither in the book nor in the toolkit. And it is not legal advice: the legal readings are reconstructions anchored to precisely cited texts, and where two official sources contradict each other the book reports both without choosing for the reader.
Need to defend a Q series decision in front of an inspector, or decide whether to move on the new Q1?
Describe your portfolio, the jurisdictions you file in, and the point where you are stuck. GuideGxP will review the request and, where appropriate, may put you in touch with a specialist matched to your technical needs and your geography.
Describe your situation →
No purchase required. Every request is reviewed before any referral to a specialist.
GuideGxP guides do not replace official regulation (ICH, EMA, European Commission, MHRA, FDA, Health Canada, Swissmedic, PMDA, PIC/S, WHO, ISO): they are operational support tools, and the user remains responsible for applying the rules in force in their own corporate context. The official texts of the ICH Q series and of the acts cited are freely available and should be kept to hand while reading: this guide does not replace them. ICH guidelines have no force of law in themselves: binding force comes from regional implementation, which this guide states jurisdiction by jurisdiction and act by act. The content on the new ICH Q1 concerns a [draft] document — Step 2b of 11 April 2025, consultation closed 30 July 2025, Step 4 expected in November 2026 — and serves readiness: at the cut-off it creates no obligation in any jurisdiction, and today's compliance remains compliance with Q1A(R2)-Q1E and with Q5C. No operational value, threshold or scoring scale is pre-loaded in the book or in the toolkit. Digital product: nothing is shipped.
